Business
Renalytix Reports Financial Results for Q1 of FY22
Renalytix Reports Financial Results for Q1 of FY22.
About this update from Renalytix Plc
[{"type":"text","content":"\n \n \n \n RNS Number : 7546U\n Renalytix PLC\n 07 December 2021\n \n \n \n \n \n \n \n Renalytix plc\n \n \n (\"Renalytix\" or the \"Company\")\n \n \n \n \n \n Renalytix Reports Financial Results for First Quarter of Fiscal Year 2022\n \n \n \n \n \n \n LONDON and SALT LAKE CITY, December 7, 2021 \n \n - Renalytix plc (NASDAQ: RNLX)\n (LSE\n : RENX), an artificial intelligence-enabled in vitro diagnostics company, focused on optimizing clinical management of kidney disease to drive improved patient outcomes and advance value-based care, today\n reported financial results for the quarter ended September 30, 2021. \n \n \n \n \n \n Recent Highlights\n \n \n · \n KidneyIntelX market access expansion continues with: \n \n \n o \n Increasing sales force deployment across VA Health system \n \n \n o \n Increasing medical science liaison (MSL) personnel nationwide\n \n \n o \n Clinical testing at Wake Forest / Atrium initiated in November\n \n \n o \n Clinical testing with Capital District Physicians Health Plan (CDPHP) initiated in November\n \n \n o \n Mount Sinai physician ordering base increased, with target testing run rate of 300 patients per week\n \n \n · \n Partnered with St. Joseph's Health, based in Syracuse, NY, part of the Trinity Health System, for KidneyIntelX deployment and to advance value-based care \n \n \n · \n Multiple private insurance coverage determinations, including Blue Cross Blue Shield coverage in two states \n \n \n · \n Expanded peer-reviewed publication of key analytical and clinical validation studies including presentation of therapeutic response data \n \n \n · \n Continued advancing KidneyIntelX regulatory strategy for diabetic kidney disease\n \n \n · \n Implemented efforts to accelerate VA Health system launch program at a national level\n \n \n · \n Continued hiring of key commercial personnel including Southeast regional sales, market access and health systems partnership directors to support expansion with Wake Forest and additional regional healthcare providers and payers \n \n \n · \n JP Morgan Healthcare Conference presentation confirmed for January 12, 2022\n \n \n \n \n \n First Quarter 2022 Financial Results\n \n \n During the three months ended September 30, 2021, the Company recognized $0.5 million o...